Boehringer Ingelheim (BI) has completed a new filling line at its commercial manufacturing facility in Shanghai, China for its contract manufacturing business, BioXcellence. The new isolator-based fill/finish line is for GMP operations for aseptic filling of liquids in vials.

BI’s BioXcellence provides contract development and manufacturing services for biopharmaceuticals for drug substances, drug products, and corresponding quality control and assurance activities through facilities in Biberach, Germany; Vienna, Austria; Fremont, California; and Shanghai.

BI inaugurated the commercial production site for biopharmaceuticals in Shanghai in May 2017. The site uses mammalian cell-culture technology and supports the company’s contract manufacturing business. BI said it constructed the facility with the long-term goal to become a leader for contract development and manufacturing of monoclonal antibodies and recombinant proteins in China. The company has been providing GMP clinical material supply at 100-L and 500-L scale in Shanghai since 2014.

Source: Boehringer Ingelheim